



PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 11/16/17  
LAST REVIEW DATE: 11/15/18  
LAST CRITERIA REVISION DATE: 11/15/18  
ARCHIVE DATE:

---

## BAXDELA™ (delafloxacin meglumine) oral tablet and intravenous infusion

---

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as “**Description**” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as “**Criteria**” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

**BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.**

---

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at [www.azblue.com/pharmacy](http://www.azblue.com/pharmacy).

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the request form in its entirety with the chart notes as documentation. All requested data must be provided. Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to [Pharmacyprecert@azblue.com](mailto:Pharmacyprecert@azblue.com). **Incomplete forms or forms without the chart notes will be returned.**

---

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 11/16/17  
LAST REVIEW DATE: 11/15/18  
LAST CRITERIA REVISION DATE: 11/15/18  
ARCHIVE DATE:

---

## BAXDELA™ (delafloxacin meglumine) oral tablet and intravenous infusion (cont.)

---

### Criteria:

➤ **Criteria for initial therapy:** Baxdela is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:

1. Individual is 18 years of age or older
2. A confirmed diagnosis of acute bacterial skin and skin structure infections (ABSSSI)
3. Current culture and sensitivity (C&S) report shows isolated pathogen is gram-positive or gram-negative organism susceptible to delafloxaicn (unless provider submits valid documentation that obtaining a C&S report is not feasible)
4. Member meets one of the following:
  - If **C&S is feasible**, one of the following:
    - Failure, contraindication or intolerance of at least 2 formulary antibiotics, one of which is fluoroquinolone, to which the isolated pathogen is susceptible
    - The C&S report shows resistance of the isolated pathogen to **ALL formulary antibiotics** FDA approved for member's diagnosis
  - If a **C&S report is not feasible** via documentation from the providers:
    - The member has failure, contraindication or intolerance to 2 formulary antibiotics indicated for member's diagnosis, one of which is a fluoroquinolone
5. There are **NO** contraindications.
  - Contraindications include:
    - Known hypersensitivity to Baxdela or any other fluoroquinolone

**Initial approval duration:** 300 mg twice daily (IV infusion) for up to 14 days only (MEDICAL BENEFIT ONLY)  
450 mg twice daily (28 tablets) for 14 days only  
Maximum duration for 14 days only regardless of route of administration

---

### Description:

- **Baxdela** is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathogens.
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of Baxdela and other antibacterial drugs, Baxdela should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
- When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 11/16/17  
LAST REVIEW DATE: 11/15/18  
LAST CRITERIA REVISION DATE: 11/15/18  
ARCHIVE DATE:

---

## BAXDELA™ (delafloxacin meglumine) oral tablet and intravenous infusion (cont.)

---

- The safety and efficacy of Baxdela were based on two phase 3, non-inferiority trials in 1,510 patients with ABSSSI. In both studies, the comparator was the intravenous (IV) combination of vancomycin and aztreonam. The primary endpoint was the objective clinical response at 48 to 72 hours post initiation of treatment, defined as  $\geq 20\%$  decrease in lesion size.

In both studies, Baxdela IV and oral monotherapy was statistically non-inferior to the combination of vancomycin plus aztreonam for the primary endpoint.

- Similar to other fluoroquinolones, Baxdela carries a boxed warning for serious adverse reactions, including tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis.
- Baxdela is contraindicated in patients with known hypersensitivity to delafloxacin or any of the fluoroquinolone class of antibacterial drugs, or any of the components of Baxdela.
- Warnings and precautions of Baxdela include hypersensitivity reactions, *Clostridium difficile*-associated diarrhea, and development of drug-resistant bacteria.
- The most common adverse reactions (incidence  $\geq 2\%$ ) with Baxdela use were nausea, diarrhea, headache, transaminase elevations, and vomiting.
- The recommended dosage of Baxdela is 300 mg by IV infusion over 60 minutes, every 12 hours or the 450 mg tablet administered orally every 12 hours for 5 to 14 days total duration.
- Baxdela may be initiated as an IV infusion and then switched to the tablet formulation at the discretion of the physician.
- Dose adjustments may be necessary for patients with renal impairment.

---

### Definitions:

**ABSSSI:** A bacterial infection of the skin with a lesion size area of at least 75 cm<sup>2</sup> (measured by the area of redness, edema, or induration).

The following infections are defined as ABSSSIs:

- Cellulitis/erysipelas: a diffuse skin infection characterized by spreading areas of redness, edema, and/or induration
- Wound infection: an infection characterized by purulent drainage from a wound with surrounding redness, edema, and/or induration
- Major cutaneous abscess: an infection characterized by a collection of pus within the dermis or deeper that is accompanied by redness, edema, and/or induration

---

### Resources:

Baxdela. Package Insert. Revised by manufacturer 6/2017. Accessed 10/12/17.

---



An Independent Licensee of the Blue Cross and Blue Shield Association

Fax completed prior authorization request form to 602-864-3126 or email to [pharmacyprecert@azblue.com](mailto:pharmacyprecert@azblue.com).  
 Call 866-325-1794 to check the status of a request.  
 All requested data must be provided. **Incomplete forms or forms without the chart notes will be returned.**  
 Pharmacy Coverage Guidelines are available at [www.azblue.com/pharmacy](http://www.azblue.com/pharmacy).

# Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

**REQUIRED:** Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Member Information			
Member Name (first & last):	Date of Birth:	Gender:	BCBSAZ ID#:
Address:	City:	State:	Zip Code:
Prescribing Provider Information			
Provider Name (first & last):	Specialty:	NPI#:	DEA#:
Office Address:	City:	State:	Zip Code:
Office Contact:	Office Phone:	Office Fax:	
Dispensing Pharmacy Information			
Pharmacy Name:	Pharmacy Phone:	Pharmacy Fax:	
Requested Medication Information			
Medication Name:	Strength:	Dosage Form:	
Directions for Use:	Quantity:	Refills:	Duration of Therapy/Use:
<input type="checkbox"/> Check if requesting <b>brand</b> only <input type="checkbox"/> Check if requesting <b>generic</b>			
<input type="checkbox"/> Check if requesting continuation of therapy (prior authorization approved by BCBSAZ expired)			
Turn-Around Time For Review			
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent. Sign here: _____ <input type="checkbox"/> Exigent (requires prescriber to include a written statement)			
Clinical Information			
<b>1. What is the diagnosis? Please specify below.</b> ICD-10 Code: _____      Diagnosis Description: _____			
<b>2. <input type="checkbox"/> Yes    <input type="checkbox"/> No      Was this medication started on a recent hospital discharge or emergency room visit?</b>			
<b>3. <input type="checkbox"/> Yes    <input type="checkbox"/> No      There is absence of ALL contraindications.</b>			
<b>4. What medication(s) has the individual tried and failed for this diagnosis? Please specify below.</b> Important note: Samples provided by the provider are not accepted as continuation of therapy or as an adequate trial and failure.			
Medication Name, Strength, Frequency	Dates started and stopped or Approximate Duration	Describe response, reason for failure, or allergy	
<b>5. Are there any supporting labs or test results? Please specify below.</b>			
Date	Test	Value	

# Pharmacy Prior Authorization Request Form

**6. Is there any additional information the prescribing provider feels is important to this review? Please specify below.**  
For example, explain the negative impact on medical condition, safety issue, reason formulary agent is not suitable to a specific medical condition, expected adverse clinical outcome from use of formulary agent, or reason different dosage form or dose is needed.

**Signature affirms that information given on this form is true and accurate and reflects office notes**

Prescribing Provider's Signature:	Date:
-----------------------------------	-------

**Please note:** Some medications may require completion of a drug-specific request form.

**Incomplete forms or forms without the chart notes will be returned.**

Office notes, labs, and medical testing relevant to the request that show medical justification are required.